Antiretroviral therapy during pregnancy and the risk of an adverse outcome [3] (multiple letters)

New England Journal of Medicine

Volumn 348, Issue 5, 2003, Pages 471-472

  Thorne, Claire ^a   Fiore, Simona ^a   Rudin, Christoph ^b   Tuomala, Ruth E ^c   Shapiro, David E ^d   Mofenson, Lynne M ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ILLICIT DRUG; PROTEINASE INHIBITOR; STREET DRUG;

BIRTH WEIGHT; CESAREAN SECTION; DRUG ABUSE; EUROPE; FEMALE; GESTATIONAL AGE; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LYMPHOCYTE COUNT; PREGNANCY; PREGNANCY COMPLICATION; PREMATURE LABOR; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; UNITED STATES; VERTICAL TRANSMISSION; VIRUS LOAD; NEWBORN; NOTE; PREMATURITY; THIRD TRIMESTER PREGNANCY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EUROPE; FEMALE; HIV INFECTIONS; HUMAN; INFANT, NEWBORN; INFANT, PREMATURE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, THIRD; STREET DRUGS; UNITED STATES; HUMANS;

EID: 0037472877     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200301303480519     Document Type: Letter

References (0)